dc.creator | Ballesteros Sánchez, Antonio | es |
dc.creator | Sánchez González, José María | es |
dc.creator | Tedesco, Giovanni Roberto | es |
dc.creator | Rocha de Lossada, Carlos | es |
dc.creator | Murano, G. | es |
dc.creator | Spinelli, Antonio | es |
dc.creator | Mazzotta, Cosimo | es |
dc.creator | Borroni, Davide | es |
dc.date.accessioned | 2024-06-03T15:45:22Z | |
dc.date.available | 2024-06-03T15:45:22Z | |
dc.date.issued | 2024-03-12 | |
dc.identifier.citation | Ballesteros Sánchez, A., Sánchez González, J.M., Tedesco, G.R., Rocha de Lossada, C., Murano, G., Spinelli, A.,...,Borroni, D. (2024). Evaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Relief. Journal of Clinical Medicine, 13 (6), 1618. https://doi.org/10.3390/jcm13061618. | |
dc.identifier.issn | 2077-0383 | es |
dc.identifier.uri | https://hdl.handle.net/11441/159630 | |
dc.description.abstract | Background: To evaluate the effects of 10% GlicoPro tear substitute therapy in patients with severe dry eye disease (DED). Methods: In this prospective longitudinal study, 30 individuals receiving 10% GlicoPro four times daily for DED were evaluated. The ocular surface disease index (OSDI) questionnaire, average non-invasive break-up time (A-NIBUT), non-anesthetic and anesthetic corneal esthesiometry (CE), ocular pain, and the presence of conjunctivochalasis (CCH) were used as clinical endpoints. Treatment compliance using dosing diaries and AEs was assessed. Results: A significant improvement was observed in the clinical endpoints: the ΔOSDI questionnaire was −39.27 ± 13.22 [−65 to −15] points, ΔA-NIBUT was 3.10 ± 1.31 [1 to 5] s, Δnon-anesthetic CE was 14 ± 6.35 [5 to 25] mm, and Δanesthetic CE was 13 ± 5.35 [5 to 20] mm (p < 0.001 for all comparisons). Ocular pain was reduced in 92.5% of the patients at the end of the follow-up. However, there was no change in the presence of CCH. In addition, all the patients were fully compliant with the dosing and no AEs related to the use of the 10% GlicoPro tear substitute were reported. Conclusions: The 10% GlicoPro tear substitute has the potential to achieve beneficial effects in ocular surface treatments. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 p. | es |
dc.language.iso | eng | es |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es |
dc.relation.ispartof | Journal of Clinical Medicine, 13 (6), 1618. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Corneal esthesiometry | es |
dc.subject | Dry eye disease | es |
dc.subject | Helix aspersa | es |
dc.subject | Ocular pain | es |
dc.subject | Tear substitute | es |
dc.title | Evaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Relief | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Física de la Materia Condensada | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Cirugía | es |
dc.relation.publisherversion | https://doi.org/10.3390/jcm13061618 | es |
dc.identifier.doi | 10.3390/jcm13061618 | es |
dc.journaltitle | Journal of Clinical Medicine | es |
dc.publication.volumen | 13 | es |
dc.publication.issue | 6 | es |
dc.publication.initialPage | 1618 | es |